As part of its ongoing expansion plans, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce the appointment of Alison Gillan as its new Management Accountant. 

Alison Gillan joins the company as Management Accountant.  Alison comes from private practice and has broad experience of in-house accounting within a wide range of businesses in many different sectors, having previously trained as a Chartered Accountant with a Big Four accountancy practice.

Dr David Ribeiro, CEO of ProAxsis, said: “As ProAxsis continues to expand, it’s important that the company brings in team members able to provide specialist expertise in key functions.  Therefore, we are delighted to welcome Alison to the team.”

Alison Gillan, newly appointed Management Accountant at ProAxsis, added: “I am so pleased to be joining the ProAxsis team at such an exciting time of development for the company.  I look forward to developing the finance function through this period of growth to enable management to make key strategic decisions.”

Due to the growing nature of the company, we continue to look for high-quality candidates to join our team.  Any new opportunities will be posted on our website –

About ProAxsis

ProAxsis Limited is a global diagnostics company, based in Northern Ireland, with a specific focus on active protease biomarkers. The company currently commercialises activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

The company has significantly expanded its product portfolio, via the recent in-licensing of a novel bone health assay from the University of Geneva, and a COVID-19 serology assay from AstraZeneca.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.  Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialisation Group.

Share This :